[go: up one dir, main page]

TN2019000004A1 - Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens. - Google Patents

Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.

Info

Publication number
TN2019000004A1
TN2019000004A1 TNP/2019/000004A TN2019000004A TN2019000004A1 TN 2019000004 A1 TN2019000004 A1 TN 2019000004A1 TN 2019000004 A TN2019000004 A TN 2019000004A TN 2019000004 A1 TN2019000004 A1 TN 2019000004A1
Authority
TN
Tunisia
Prior art keywords
cancer
treatment
formula
vita
major
Prior art date
Application number
TNP/2019/000004A
Other languages
English (en)
Inventor
Ghidhaoui Abir
Original Assignee
Ghidhaoui Abir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghidhaoui Abir filed Critical Ghidhaoui Abir
Priority to TNP/2019/000004A priority Critical patent/TN2019000004A1/fr
Priority to PCT/TN2019/000008 priority patent/WO2020145905A1/fr
Publication of TN2019000004A1 publication Critical patent/TN2019000004A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La combinaison innovante des différents agents biologiques a permis l'élaboration d'une formule traitante sous forme de perfusion intraveineuse, pour le traitement de six (6) types de cancer qui sont : Le cancer du tissu mammaire Le cancer de l'ovaire Le cancer de la prostate Le cancer de l'estomac Le cancer de la vessie La procédure d'expérimentation était préparée durant 40 mois. L'expérimentation de la formule était réalisée en comparaison avec le traitement «cisplatine» de MYLAN et le traitement «5-fluouracile» de TEVA. Ce traitement est favorisé par rapport les autres traitements sur le marché car il assure la provocation de la procédure de la mort cellulaire des cellules cancéreuse durant une durée plus courte que la durée de la mort cellulaire en utilisant les autres formules. Aussi, la formulation de VITA provoque l'apoptose cellulaire «sélectif» sans les effets negatifs majeurs et moyens. Cette formule est destinée strictement pour l'industrie pharmaceutique.
TNP/2019/000004A 2019-01-08 2019-01-08 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens. TN2019000004A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TNP/2019/000004A TN2019000004A1 (fr) 2019-01-08 2019-01-08 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.
PCT/TN2019/000008 WO2020145905A1 (fr) 2019-01-08 2019-02-19 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TNP/2019/000004A TN2019000004A1 (fr) 2019-01-08 2019-01-08 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.

Publications (1)

Publication Number Publication Date
TN2019000004A1 true TN2019000004A1 (fr) 2020-07-15

Family

ID=66484117

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2019/000004A TN2019000004A1 (fr) 2019-01-08 2019-01-08 Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.

Country Status (2)

Country Link
TN (1) TN2019000004A1 (fr)
WO (1) WO2020145905A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20031927A3 (cs) * 2001-01-09 2003-10-15 Merck Patent Gmbh Farmaceutický prostředek na bázi inhibitorů receptoru tyrosinkinázy a inhibitorů angiogeneze
US20060293264A1 (en) * 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
US20100150844A1 (en) * 2006-07-28 2010-06-17 The Johns Hopkins University Use of 8-quinolinol and its analogs to target cancer stem cells

Also Published As

Publication number Publication date
WO2020145905A1 (fr) 2020-07-16

Similar Documents

Publication Publication Date Title
CN1338932A (zh) 硫辛酸与抗坏血酸组合在治疗癌症中的应用
US20210338686A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CN109906081A (zh) 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
Levi et al. Stress impairs the efficacy of immune stimulation by CpG-C: Potential neuroendocrine mediating mechanisms and significance to tumor metastasis and the perioperative period
CN109692326A (zh) 一种蜂毒脂质纳米颗粒的应用
RU2057528C1 (ru) Способ химиотерапии злокачественных опухолей
WO2015172712A1 (fr) Composition pharmaceutique pour injection avec effet synergique de la vitamine c et des médicaments antitumoraux
ES2656913T3 (es) Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes
TN2019000004A1 (fr) Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens.
Keller et al. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin’s lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207
CN101920015A (zh) 一种治疗癌症的药物组合物
TWI768686B (zh) 一種抗雙重打擊淋巴瘤的聯合用藥物組成物及其應用
EA014603B1 (ru) Противоопухолевая, антибактериальная и антивирусная фармацевтическая композиция (варианты)
JPS60501408A (ja) 酸化剤ストレス誘導抗生物質に対する動物許容度を増加させる方法及び薬剤
Abed et al. Embryogenic effects of doxorubicin in chicken embryo
CN1972955B (zh) 放射增敏剂
Tabaru et al. Treatment of VX2 carcinoma implanted in the liver with arterial and intraperitoneal administration of oily anticancer agents.
CN104703626B (zh) 用于治疗癌症的基于碘油的抗肿瘤乳剂
Ning et al. Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo
ES2415907T3 (es) Combinación terapéutica que comprende un inhibidor de cinasas aurora y agentes antiproliferativos
US20100280125A1 (en) Medicinal agent
JP2021533107A (ja) 癌を治療するための併用療法
Shafik Intratunical injection of methotrexate for the treatment of seminoma of the testicle
Mao et al. Combination of carboplatin and photodynamic therapy with 9-hydroxypheophorbide ɑ enhances mitochondrial and endoplasmic reticulum apoptotic effect in AMC-HN-3 laryngeal cancer cells
Clarkson The elusive goal: Presidential address